Time for Wegovy to treat more than just obesity: Lisa Jarvis
In a groundbreaking analysis, Novo Nordisk's Wegovy emerges as more than just an obesity treatment—it's a potential game-changer for heart health. Contrary to conventional beliefs, its benefits extend beyond weight loss, significantly reducing the risk of cardiovascular events. Could GLP-1 drugs like Wegovy and Eli Lilly's Mounjaro redefine treatment paradigms, transcending the "obesity" label to become primary heart medications? With mounting evidence, the conversation shifts towards broader health impacts and equitable access, offering hope for a future where heart failure's alarming rise may be reversed.
Sign up for your early morning brew of the BizNews Insider to keep you up to speed with the content that matters. The newsletter will land in your inbox at 5:30am weekdays. Register here.
By Lisa Jarvis
A new analysis found that the profound benefits of Novo Nordisk's obesity drug Wegovy for people at risk of heart attacks or strokes don't depend on the number of the scale—cardiovascular health improves whether people lose a lot or even very little weight.
___STEADY_PAYWALL___